Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart-Healthy supplement may counter painkiller risks

NCT ID NCT04765644

Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether taking L-arginine, a natural amino acid, could prevent blood vessel damage caused by the painkiller celecoxib. Forty-four healthy men took either celecoxib alone, celecoxib plus L-arginine, or placebos for one week. Researchers measured changes in blood vessel function and stiffness to see if the supplement offered protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
L-arginine (an amino acid supplement) and celecoxib (an NSAID painkiller)
What this could lead to
If it works, this could point toward a way to reduce heart risks from common painkillers like celecoxib.
What could go wrong
This was a small, early-phase study in only 44 healthy men, so results may not apply to the general public or people with health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

44 people

The number who actually took part.

Started

Jun 2021

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * No abnormal findings on medical history, screening physical examination, hematology, biochemistry, urinalysis (including specific gravity), and vital signs (sitting blood pressure, sitting pulse rate, sitting respiratory rate and body temperature) within 2 weeks of commencement of the study. * Normal fasting lipid profile * Non-smoking * Clear venous access in upper limbs * BMI: 18-30 * No history or signs of drug abuse * No other medication 4 weeks before or during the study * Informed written consent Exclusion Criteria: * Any history of allergy to NSAIDS or arginine * Significant medical conditions * Pulse rate \<50 bpm * Sitting systolic blood pressure \<80 or \>160 mmHg * Sitting diastolic pressure \<60 or \>100 mmHg * Baseline endothelial dysfunction (as defined by EndoPAT; LnRHI \<0.51) * Participation in other clinical study 8 weeks before or during the study * Donation of blood 8 weeks before or during the study * Those on medication that cannot be discontinued

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • Imperial College Clinical Research Facility

    London, w12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.